Optimal duration of oral anticoagulant therapy following deep vein thrombosis of lower limbs

Blood Coagulation and Fibrinolysis

Volumn 7, Issue 5, 1996, Pages 507-514

  Bounameaux, H ^a   De Moerloose, P ^a   Sarasin, F P ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Bleeding complications; Deep vein thrombosis; Duration of treatment; Oral anticoagulants; Pulmonary embolism; Thromboembolic recurrence

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

BLEEDING; DEEP VEIN THROMBOSIS; HUMAN; LOWER LEG; LUNG EMBOLISM; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM;

EID: 0029832559     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199607000-00001     Document Type: Review

References (37)

1. Weinmann EE, Salzman EW. Deep-vein thrombosis. N Engl J Med 1994; 331: 1630-1641.
2. Büller HR, Lensing AWA, Hirsh J, ten Cate JW. Deep vein thrombosis: new non-invasive diagnostic tests. Thromb Haemost 1991; 66: 133-137.
3. Stein PD, Hull RD. Strategy that includes serial noninvasive leg tests for diagnosis of thromboembolic disease in patients with suspected acute pulmonary embolism based on data from PIOPED. Arch Intern Med 1995; 155: 2101-2104.
4. Perrier A, Bounameaux H, Morabia A, et al. Diagnosis of pulmonary embolism by a decision analysis based strategy including clinical probability, D-dimer and ultrasonography: a management study. Arch Intern Med 1996; 156: 531-536.
5. Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 1992; 102: 408S-425S.
6. Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 1995; 108: 335S-351S.
7. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993; 95: 315-328.
8. Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 1992; 340: 873-876.
9. Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332: 1661-1665.
10. Levine MN, Hirsh J, Gent M, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995; 74: 606-611.
11. Sarasin FP, Bounameaux H. Duration of oral anticoagulant therapy after proximal deep vein thrombosis: a decision analysis. Thromb Haemost 1994; 71: 286-291.
12. O'Sullivan EF. Duration of anticoagulant therapy in venous thrombo-embolism. Med J Aust 1972; 2: 1104-1107.
13. Schulman S, Lockner D, Juhlin-Dannfelt A. The duration of oral anticoagulation after deep vein thrombosis. Acta Med Scand 1985; 217: 547-552.
14. Holmgren KAJ, Andersson G, Fagrell B, et al. One-month versus six-month therapy with oral anticoagulants after symptomatic deep vein thrombosis. Acta Med Scand 1985; 218: 279-284.
15. Beyth RJ, Cohen AM, Landefeld CS. Long term outcomes of deep-vein thrombosis. Arch Intern Med 1995; 155: 1031-1037.
16. Prandoni P, Lensing AWA, Cogo A, et al. The clinical course of deep-vein thrombosis. Thromb Haemost 1995; 73: 1092 (abstract).
17. Prandoni P, Lensing AWA, Büller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992, 339: 441-445.
18. Koopman MWM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996; 334: 682-687.
19. Moser KM, LeMoine JR. Is embolic risk conditioned by location of deep venous thrombosis? Ann Intern Med 1981; 94: 439-444.
20. Prandoni P, Lensing AWA, Büller HR, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992; 327: 1128-1133.
21. Bynum LJ, Wilson JE III. Low-dose heparin therapy in the long-term management of venous thromboembolism. Am J Med 1979; 67: 553-556.
22. Hull R, Delmore T, Genton E, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979; 301: 855-858.
23. Hull R, Delmore T, Carter C, et al. Adjusted subcutaneous heparin versus warfarin sodium in the long term treatment of venous thrombosis. N Engl J Med 1982; 306: 189-194.
24. Hull R, Hirsh J, Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982; 307: 1676-1681.
25. Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for five days as compared with ten days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990; 322: 1260-1264.
26. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-982.
27. Brandjes DP, Heijboer H, Büller HR, et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal vein thrombosis. N Engl J Med 1992; 327: 1485-1489.
28. Simonneau G, Charbonnier B, Decousus H, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med 1993; 153: 1541-1546.
29. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993; 95: 315-328.
30. Hirsh J. The optimal duration of anticoagulant therapy for venous thrombosis (Editorial). N Engl J Med 1995; 332: 1710-1711.
31. Chesterman CN. After a first episode of venous thromboembolism. Stop anticoagulant treatment after four to six weeks in patients with 'reversible' risk factors (Editorial). Br Med J 1995; 311: 700-701.
32. Lagerstedt CL, Olsson CG, Fagher BO, Oqvist BW, Albrechtsson U. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985; 2: 515-518.
33. Bona RD, Sivjee KY, Hickey AD, Wallace DM, Wajcs SB. The efficacy and safety of oral anticoagulation in patients with cancer. Thromb Haemost 1995; 74: 1055-1058.
34. Landefeld CS, Goldman L. Major bleeding in out-patients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87: 144-152.
35. Eckman MH, Levine HJ, Pauker SG. Effect of laboratory variation in the prothrombin-time ratio on the results of oral anticoagulant therapy. N Engl J Med 1993; 329: 696-702.
36. Landefeld CS, Anderson PA. Guideline-based consultation to prevent anticoagulant-related bleeding. A randomized, controlled trial in a teaching hospital. Ann Intern Med 1992; 116: 829-837.
37. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-1134.